Mesoblast Limited

NASDAQ:MESO

Biotechnology

Healthcare
$11.64 +1.86%

+$0.26 today

Market cap
$1.51B
Beta
0.79
P/E (TTM)
-23.6
EPS (TTM)
-$0.06
52W Low $9.88High $21.50

Volume 0.13M

Average 0.21M

MESO EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Mesoblast LimitedNASDAQ: MESO

EBITDA · Q4 FY2026 · quarter ended Jun 2026

EBITDA remains negative

Q4 FY2026 EBITDA was -$9.97M, compared with -$19.64M a year earlier. Trailing-twelve-month EBITDA was -$45.01M.

Context

  • EBITDA amounted to 35.5% of revenue in FY2026, down 392.8 pp from a year earlier.
  • EBITDA grew in size in 1 of the last 3 fiscal years.
  • FY2026 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 3 analysts of $4.72M (+111.0%) for the fiscal year ending Jun 2027, a step up from the +41.8% reported in FY2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$9.97M+0.0% QoQ
Last fiscal yearJun 2026
-$42.88M+41.8% YoY
LTMJun 2026
-$45.01M+22.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+49.2%+53.1%+3.8 pp
1 year+41.8%+111.0%+69.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2026
(42.88M) USD
Year-over-year change
+41.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How MESO compares with its peers on the latest reported figures

  • MESO's LTM Jun 2026 EBITDA of -$45.01M is the 4th highest of the 6 companies compared; the peer median is -$43.15M.
  • Its year-over-year change of +22.6% is the 4th highest of 6, against a peer median of +23.4%.
  • EBITDA amounts to 37.4% of revenue for MESO, versus a peer median of 292.2%.
MESO Competitors Peer median
EBITDA for MESO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$893.33M +1767.7%——
LEGNLegend Biotech CorporationLTM Sep 2026$99.55M +154.3%—7.3%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026-$43.15M -177.1%—291.9%
MESOMesoblast LimitedLTM Jun 2026-$45.01M +22.6%—37.4%
CELUCelularity Inc.LTM Dec 2025-$77.62M -86.2%—292.4%
FATEFate Therapeutics, Inc.LTM Mar 2026-$117.42M +23.4%—1859.1%
Peer median (excluding MESO) -$43.15M+23.4%—292.2%

Competitors are the stored peer set for MESO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Revenue10.21M7.5M5.9M17.2M120.79M
Cost of Revenue63.57M54.92M41.07M5.13M19.21M
Gross Profit(53.36M)(47.42M)(35.17M)12.07M101.58M
Gross Margin-522.6%-632.2%-595.9%70.2%84.1%
Research & Development32.82M27.19M25.35M34.81M97.94M
Selling, General & Admin57.97M53.11M23.63M39.31M55.13M
Operating Expenses90.79M76.79M48.98M74.51M153.08M
Depreciation & Amortization4.38M4.11M1.9M6.4M8.62M
EBITDA(76.57M)(58.55M)(56.08M)(73.66M)(42.88M)
EBITDA Margin-749.9%-780.6%-950.1%-428.3%-35.5%
Operating Income(80.57M)(69.29M)(84.15M)(62.44M)(51.5M)
Operating Margin-789.1%-923.7%-1425.7%-363.1%-42.6%
Interest Income0831K1.82M3.55M3.93M
Interest Expense17.29M19.44M20.66M22.93M23.95M
Other Income / Expenses(10.48M)(12.81M)(4M)(39.37M)(5.64M)
Income Before Tax(91.59M)(82.1M)(88.15M)(101.81M)(57.14M)
Pre-Tax Margin-896.9%-1094.5%-1493.5%-592.0%-47.3%
Income Tax Expense(239K)(212K)(191K)330K615.74K
Net Income(91.35M)(81.89M)(87.96M)(102.14M)(57.76M)
Net Margin-894.6%-1091.7%-1490.3%-593.9%-47.8%
EPS (Basic)(1.30)(0.98)(0.89)(0.84)(0.45)
EPS (Diluted)(1.30)(0.98)(0.89)(0.84)(0.45)
Weighted Avg Shares68.27M83.77M98.67M120.78M129.49M
Weighted Avg Shares (Diluted)68.29M83.93M98.67M120.78M129.49M

Mesoblast Limited

NASDAQ:MESO

Intrinsic Alpha fair value

Locked

Current Price

$11.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.